Show simple item record

dc.contributor.authorParsamanesh N.
dc.contributor.authorMoossavi M.
dc.contributor.authorBahrami A.
dc.contributor.authorFereidouni M.
dc.contributor.authorBarreto G.
dc.contributor.authorSahebkar A.
dc.date.accessioned2020-09-02T22:25:23Z
dc.date.available2020-09-02T22:25:23Z
dc.date.issued2019
dc.identifier10.1016/j.intimp.2019.05.006
dc.identifier.citation73, , 146-155
dc.identifier.issn15675769
dc.identifier.urihttps://hdl.handle.net/20.500.12728/5760
dc.descriptionActivation of NOD-like receptor (NLR)family and pyrin domain containing 3 (NLRP3)inflammasome contributes to inflammation and may lead to atherosclerosis. The NLRP3 inflammasome as a molecular platform regulates the activation of ATP signaling, K+ efflux, cathepsin-B activity, lysosomal function and pro-inflammatory cytokines (i.e. IL-1β and IL-18). Statins has been widely prescribed for the treatment of hyperlipidemia and cardiovascular diseases. In addition to lipid-lowering effect, statins have immunomodulatory, anti-inflammatory, antioxidant and antiapoptotic functions. An increasing number of studies indicated NLRP3 inflammasome and their downstream mediators as important targets for statin drugs in inflammatory diseases. In this review, we discussed different aspect of the NLRP3 inflammasome signaling pathways and focused on the effect of statin drugs on NLRP3 inflammasomes in association to atherosclerosis in order to elucidate possible targets for future research and clinical settings. © 2019 Elsevier B.V.
dc.language.isoen
dc.publisherElsevier B.V.
dc.subjectAcute coronary syndrome
dc.subjectCoronary atherosclerosis
dc.subjectInflammation
dc.subjectNLRP3
dc.subjectNOD-like receptor
dc.subjectantiinflammatory agent
dc.subjectcryopyrin
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitor
dc.subjectinflammasome
dc.subjectcryopyrin
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitor
dc.subjectatherosclerosis
dc.subjectcardiovascular disease
dc.subjectdisease association
dc.subjectdrug efficacy
dc.subjectdrug targeting
dc.subjecthuman
dc.subjectnonhuman
dc.subjectpriority journal
dc.subjectprotein assembly
dc.subjectprotein family
dc.subjectprotein function
dc.subjectrandomized controlled trial (topic)
dc.subjectReview
dc.subjectsignal transduction
dc.subjectanimal
dc.subjectatherosclerosis
dc.subjectimmunology
dc.subjectAnimals
dc.subjectAtherosclerosis
dc.subjectHumans
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors
dc.subjectNLR Family, Pyrin Domain-Containing 3 Protein
dc.titleNLRP3 inflammasome as a treatment target in atherosclerosis: A focus on statin therapy
dc.typeReview


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record